+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Malignant Pleural Mesothelioma (MPM) - Market Insights, Epidemiology and Market Forecast - 2030

  • ID: 5135439
  • Report
  • August 2020
  • Region: Global
  • 239 pages
  • DelveInsight

FEATURED COMPANIES

  • AstraZeneca
  • Bayer/ImmunoGen/MorphoSys
  • Hoffmann-La Roche
  • MedImmune LLC
  • Merck Sharp & Dohme Corp.
  • Momotaro-Gene
  • MORE
The ‘Malignant Pleural Mesothelioma (MPM)-Market Insights, Epidemiology and Market Forecast - 2030’ report delivers an in-depth understanding of the MPM, historical and forecasted epidemiology as well as the MPM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

The MPM market report provides current treatment practices, emerging drugs, MPM market share of the individual therapies, current and forecasted MPM market size from 2017 to 2030 segmented by seven major markets. The Report also covers current MPM treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2017-2030

Malignant Pleural Mesothelioma (MPM): Disease Understanding and Treatment Algorithm

Malignant Pleural Mesothelioma Overview

Mesothelioma is a rare, aggressive form of malignant tumor that is caused by inhaled asbestos fibers and forms in the lining of the lungs, abdomen or heart. Pleural mesothelioma is a cancer of the pleura, which is the mesothelium surrounding the lungs and it is the most common type of the mesothelioma, accounting for 80 - 90% of all diagnosed cases. Because males are exposed to asbestos more often, they are more likely to be diagnosed with mesothelioma. The main risk factor for pleural mesothelioma is exposure to asbestos. Asbestos is a group of minerals that occur naturally as bundles of tiny fibers. These fibers are found in soil and rocks in many parts of the world. When asbestos fibers in the air are inhaled, they can get into the lungs. Fibers that stay in the lungs can travel to the ends of the small airways and enter the pleural lining of the lung and chest wall.

Malignant Pleural Mesothelioma Diagnosis

The initial clinical presentation of mesothelioma may be dyspnea, generally associated with developing pleural effusion. Pleural pain, not related to breathing movements, is also a common manifestation. Weight loss and other symptoms are rare in the early stages, but as the condition advances, marked hemithorax retraction is often observed, and pain becomes particularly intense and persistent. Standard diagnostic workup in patients with MPM includes Chest X-ray, computed tomography (CT) scan of the chest and upper abdomen, PET, MRI to define the extension of the disease. Invasive procedures are required to obtain specimens for a definitive histological and bio-molecular diagnosis. Additional investigations include blood markers and pulmonary function tests.

Malignant Pleural Mesothelioma Treatment

Treatment strategies for MPM include chemotherapy, radiation, and surgery. Sometimes specialists may use combination of the above-mentioned approaches which is called multimodal therapy. MPM patients who are diagnosed in early stages get benefitted the most from surgery. The main goal of surgery for MPM is to remove all visible tumor, with the hope that chemotherapy and/or radiation can eliminate residual microscopic disease. Presently, there are two main procedures that are being practiced for MPM management - Pleurectomy and Decortication (P/D), and Extrapleural Pneumonectomy (EPP). These surgical procedures are performed through an open incision in the chest, known as thoracotomy. EPP considered being the best and more aggressive surgical selection among both choices. The EPP removes the pleura, the entire cancerous lung, the diaphragm, and the heart sac (pericardium). On the other hand, pleurectomy and decortication, or radical pleurectomy, involves removing the tumors and affected pleura (lining of the lung). Apart from this, in May 2019, the US FDA approved the NovoTTF-100L System in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable locally advanced or metastatic malignant pleural mesothelioma. Additionally, In August 2018, Ono and BMS announced that the companies have received approval for Opdivo for an expanded indication of unresectable advanced MPM.

Malignant Pleural Mesothelioma (MPM) Epidemiology

The MPM epidemiology division provide the insights about historical and current MPM patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The total Incident cases of MPM in the 7MM were observed to be 11,431 cases in 2017 which are estimated to decline during the study period (2017-2030).

The disease epidemiology covered in the report provides historical as well as forecasted MPM epidemiology [segmented as Total Incidence of Mesothelioma, Total Incident Cases of MPM, Total Incident Cases of MPM Segmented by Age and Gender, Total Type-specific Cases of MPM, Total Incident Cases of MPM by Stages, and Treated Patient Pool of MPM] scenario of MPM in the 7MM covering United States, EU5 countries (Germany, France, Italy , Spain, and United Kingdom), and Japan from 2017 to 2030.

Country Wise- Malignant Pleural Mesothelioma Epidemiology

Mesothelioma incidence rates in most of the 7MM countries (except Spain and Japan) are in the declining trend due to reduced population wide exposure to asbestos. Among the European Countries, highest MPM incident cases observed in the UK in 2017.

Malignant Pleural Mesothelioma Drug Chapters

Drug chapter segment of the Malignant Pleural Mesothelioma report encloses the detailed analysis of Malignant Pleural Mesothelioma marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Malignant Pleural Mesothelioma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Malignant Pleural Mesothelioma Marketed Drugs

Opdivo (Nivolumab): Bristol-Myers Squibb/ONO Pharmaceutical

Opdivo (Nivolumab) by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1, with immune checkpoint inhibitory and antineoplastic activities. In Japan, ONO launched Opdivo for the treatment of unresectable advanced or recurrent malignant pleural mesothelioma which has progressed after chemotherapy in August 2018. For MPM, it is approved only in Japan; however, in the US and Europe, it is currently in phase III clinical trial.

NovoTTF-100L System in Combination with Chemotherapy: NovoCure

NovoTTF-100L - a product of NovoCure is a noninvasive, antimitotic cancer treatment that delivers tumor treating fields to the region of the tumor, a therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. It has been approved by the US FDA for the first-line treatment of unresectable, locally advanced, or metastatic, malignant pleural mesothelioma. It is worth mentioning that, NovoCure has applied for CE certification to market NovoTTF-100L in the EU.

Products detail in the report.

Malignant Pleural Mesothelioma Emerging Drugs

TR002: Trizell

Trizell is evaluating its gene therapy TR002, an adenovirus-mediated interferon alfa 2b (rAd-IFN),in ongoing phase III clinical study in patients with malignant pleural mesothelioma who have failed the first-line standard of care chemotherapy. It is administered by catheter into the pleural cavity, where the virus enters the cells lining the pleural cavity. Inside the cells, the virus breaks down leaving the active gene to do its work. A previous Phase II study of TR002 is at Penn Medicine’s Abramson Cancer Center included 40 mesothelioma patients who were newly diagnosed or failed standard chemotherapy (Pemetrexed, and Cisplatin). Patients showed an overall disease control rate of 87.5%.

Imfinzi: AstraZeneca

Imfinzi (durvalumab; MEDI4736) - a product of AstraZeneca, is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody. PrECOG, a cancer research group formed as a not-for-profit limited liability company in 2006 by the ECOG Research and Education Foundation, with funding from AstraZeneca, has initiated clinical trials investigating Imfinzi, in first Line treatment in Advanced Pleural Mesothelioma patients. At present two clinical trials are ongoing, which are NCT02899195 (PrE0505), and NCT04334759 (DREAM3R).

Tecentriq Plus Avastin: Hoffmann-La Roche

Tecentriq (Atezolizumab) is a product of Roche. It is a programmed cell death ligand 1 (PD-L1) blocking antibody which works by blocking the action of a certain protein in cancer cells. This helps the immune system to fight against the cancer cells and helps to slow tumor growth. Presently, the company in collaboration with the European Thoracic Oncology Platform (Sponsor) is involved in a multicenter randomized Phase III trial (NCT03762018) comparing Atezolizumab plus Bevacizumab and standard chemotherapy vs. bevacizumab and standard chemotherapy as first-line treatment for Advanced Malignant Pleural Mesothelioma.

Pegargiminase: Polaris Pharmaceuticals

Pegargiminase (ADI‑PEG 20), an arginine degrading enzyme is a product of Polaris Pharmaceuticals currently being investigated in ATOMIC-Meso Phase II/III Study (NCT02709512) clinical study. Pegargiminase is administered by intramuscular injection and works by depleting the external supply of an amino acid called arginine.

MTG201 Plus Nivolumab: Momotaro-Gene

MTG201 is novel investigational gene therapy with unique dual mechanisms of action capable of addressing a range of cancers. In September 2019, Momotaro-Gen announced enrollment of first patients with Relapsed Malignant Pleural Mesothelioma. The Phase II trial (NCT04013334), which is being conducted at the Baylor College of Medicine is an open-label, single-arm study designed to assess the efficacy, safety, and tolerability of intratumoral administration of MTG201 in combination with nivolumab. Apart from this, Momotaro-Gene has completed Phase I trial of MTG201, demonstrating encouraging safety and tolerability in patients with malignant. This study was conducted with relapsed malignant pleural mesothelioma patients in Japan by Kyorin Pharmaceuticals.

Products detail in the report.

Malignant Pleural Mesothelioma Market Outlook

Key Findings

According to the publisher, Malignant Pleural Mesothelioma market in the 7MM is expected to change in the study period 2017-2030. The therapeutic market of Malignant Pleural Mesothelioma in seven major markets was found to be USD 290 million in 2017 which is expected to increase during study period (2017-2030).

The United States Market Outlook

In 2017, the total market size of MPM therapies was found to be USD 112 million in the United States which is expected to increase in the study period (2017-2030).

EU-5 Countries: Market Outlook

In 2017, the total market size of MPM therapies was found to be USD 142 million in the EU-5 countries which is expected to increase in the study period (2017-2030).

Japan Market Outlook

The total market size of MPM therapies in Japan was found to be USD 36 million in 2017.

Malignant Pleural Mesothelioma Pipeline Development Activities

The drugs which are in pipeline includes:

1. TR002 (nadofaragene firadenovec; rAd-IFN): Trizell Ltd: Phase III

2. Imfinzi (durvalumab; MEDI4736): AstraZeneca: Phase III

3. Tecentriq (Atezolizumab) Plus Avastin (Bevacizumab): Hoffmann-La Roche: Phase III

4. MesoPher (Vaccine): Polaris Pharmaceuticals: Phase II/III

5. Pegargiminase (ADI PEG 20): Polaris Pharmaceuticals: Phase II/III

6. Keytruda (MK-3475; Pembrolizumab): Merck Sharp & Dohme Corp.: Phase II/III

7. GALINPEPIMUT-S (Vaccine): Sellas Life Sciences Group: Phase II

8. MTG201 Plus Nivolumab: Momotaro-Gene: Phase II

9. Anetumab ravtansine (BAY 94-9343): Bayer/ImmunoGen/MorphoSys: Phase II

10. Lurbinectedin: PharmaMar: Phase II

11. Yondelis (trabectedin): PharmaMar: Phase II

12. Tremelimumab: MedImmune LLC: Phase II

13. Nintedanib (BIBF 1120): Boehringer Ingelheim Limited: Phase II

List is not exhaustive, full list and Products detail will be provided in the report.

Pipeline Development Activities

Key Points

1. In December 2019, PharmaMar and Jazz signed an agreement of exclusive license for the commercialization of lurbinectedin in the United States. In January 2020, PharmaMar received the initial payment of 200 million down payment on behalf of the agreement signed with Jazz Pharmaceuticals

2. In July 2019, TCR2 Therapeutics announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to collaborate on the use of TCR2’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuCTM-T cells) as a cancer therapeutic agent against mesothelin in the Company’s ongoing Phase I/II trial of TC-210.

3. In February 2019, the US FDA have granted orphan drug designation to TC-210 for the treatment of mesothelioma.

Malignant Pleural Mesothelioma Drugs Uptake

Among emerging therapies, nivolumab in combination with ipilimumab whose topline phase III results recently announced by BMS in first line setting is expected to have an edge over Optune plus chemotherapy regimen owing to physicians familiarities, NCCN is already recommending the combo in second line or later setting and also nivolumab monotherapy is already approved in Japan for relapsed or refractory pool; nivolumab plus ipilimumab combo expected to generate significant revenue by 2030, due to expected entry of biosimilars in upcoming years erosion in sales value of Opdivo is anticipated

Access and Reimbursement Scenario in Malignant Pleural Mesothelioma Therapies
  • In January 2008, National Institute for Health and Care Excellence (NICE), recommended Pemetrexed as a treatment option for malignant pleural mesothelioma only in people who have a World Health Organization (WHO) performance status of 0 or 1, who are considered to have advanced disease and for whom surgical resection is considered inappropriate
KOL- Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Malignant Pleural Mesothelioma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Malignant Pleural Mesothelioma market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitive and Market Intelligence analysis of the Malignant Pleural Mesothelioma Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of Malignant Pleural Mesothelioma, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
  • Comprehensive insight has been provided into the Malignant Pleural Mesothelioma epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Malignant Pleural Mesothelioma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Malignant Pleural Mesothelioma market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Malignant Pleural Mesothelioma market.
Report Highlights
  • In the coming years, Malignant Pleural Mesothelioma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Malignant Pleural Mesothelioma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Malignant Pleural Mesothelioma. Launch of emerging therapies, will significantly impact the Malignant Pleural Mesothelioma market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Malignant Pleural Mesothelioma.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Malignant Pleural Mesothelioma Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Malignant Pleural Mesothelioma Pipeline Analysis
  • Malignant Pleural Mesothelioma Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Malignant Pleural Mesothelioma Report Key Strengths
  • 11 Years Forecast
  • 7MM Coverage
  • Malignant Pleural Mesothelioma Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake
Malignant Pleural Mesothelioma Report Assessment
  • SWOT Analysis
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Conjoint Analysis
  • Market Attractiveness
  • Market Drivers and Barriers
Key Questions

Market Insights:
  • What was the Malignant Pleural Mesothelioma Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Malignant Pleural Mesothelioma total market Size as well as market size by therapies across the 7MM during the study period (2017-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Malignant Pleural Mesothelioma market size during the study period (2017-2030)?
  • At what CAGR, the Malignant Pleural Mesothelioma market is expected to grow in the 7MM during the study period (2017-2030)?
  • What would be the Malignant Pleural Mesothelioma market outlook across the 7MM during the study period (2017-2030)?
  • What would be the Malignant Pleural Mesothelioma market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
  • Malignant Pleural Mesothelioma patient types/ pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
  • How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration and frequencies based on their clinical trial results?
  • Among the emerging therapies, what are the potential therapies which are expected to disrupt the Malignant Pleural Mesothelioma market?
Epidemiology Insights:
  • What is the disease risk, burden and unmet needs of the Malignant Pleural Mesothelioma?
  • What is the historical Malignant Pleural Mesothelioma patient pool in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What would be the forecasted patient pool of Malignant Pleural Mesothelioma in 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Malignant Pleural Mesothelioma?
  • Out of all the 7MM countries, which country would have the highest Incident population of Malignant Pleural Mesothelioma during the study period (2017-2030)?
  • At what CAGR the population is expected to grow in the 7MM during the study period (2017-2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Malignant Pleural Mesothelioma?
  • What % of MPM patients diagnosed with the most advanced stage of cancer at diagnosis? And what % of patients with local or regional stage are progressing to distant stage?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the treatment of Malignant Pleural Mesothelioma along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Malignant Pleural Mesothelioma in the US, Europe and Japan?
  • What are the Malignant Pleural Mesothelioma marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Malignant Pleural Mesothelioma?
  • How many therapies are developed by each company for the treatment of Malignant Pleural Mesothelioma?
  • How many emerging therapies are in mid stage, and late stage of development for the treatment of Malignant Pleural Mesothelioma?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Malignant Pleural Mesothelioma therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Malignant Pleural Mesothelioma and their status?
  • What are the key designations that have been granted for the emerging therapies for Malignant Pleural Mesothelioma?
  • What are the global historical and forecasted market of Malignant Pleural Mesothelioma?
Reasons to buy
  • The report will help in developing business strategies by understanding trends shaping and driving the Malignant Pleural Mesothelioma market.
  • To understand the future market competition in the Malignant Pleural Mesothelioma market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Malignant Pleural Mesothelioma in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Malignant Pleural Mesothelioma market.
  • To understand the future market competition in the Malignant Pleural Mesothelioma market.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca
  • Bayer/ImmunoGen/MorphoSys
  • Hoffmann-La Roche
  • MedImmune LLC
  • Merck Sharp & Dohme Corp.
  • Momotaro-Gene
  • MORE
1. Key Insights

2. Executive Summary of Malignant Pleural Mesothelioma (MPM)

3. SWOT Analysis of Malignant Pleural Mesothelioma (MPM)

4. Malignant Pleural Mesothelioma: Market Overview at a Glance

5. Malignant Pleural Mesothelioma (MPM): Disease Background and Overview
5.1. Introduction
5.2. Malignant Pleural Mesothelioma (MPM)
5.2.1. Signs and Symptoms of MPM
5.2.2. Risk Factors and Causes of MPM
5.2.3. Pathophysiology of MPM

6. Diagnosis of MPM
6.1. Chest X-ray
6.2. Thoracic ultrasound (US)
6.3. CT scan
6.4. Magnetic resonance imaging (MRI)
6.5. PET-CT scan
6.6. Thoracentesis
6.7. Pleural Biopsy
6.7.1. CT-guided Core Biopsy
6.7.2. Abrams Needle Biopsy
6.7.3. Open Biopsy
6.7.4. Thoracoscopic Biopsy
6.8. SMRP Blood Test
6.9. Histological Diagnosis of MPM
6.10. Biomarkers in the Diagnosis of MPM
6.11. Stages of MPM
6.11.1. The TNM Staging System

7. Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM

8. Epidemiology Scenario: 7MM
8.1. Total Incident Cases of Mesothelioma in the 7MM
8.2. Total Incident Cases of MPM in the 7MM
8.3. Gender-specific Cases of MPM in the 7MM
8.4. Age-specific Cases of MPM in the 7MM
8.5. Type-specific Cases of MPM in the 7MM
8.6. Total Incident Cases of MPM by Stages in the 7MM
8.7. Treated cases of MPM in the 7MM

9. The United States Epidemiology
9.1. Total Incident Cases of MPM in the US
9.2. Gender-specific Cases of MPM in the US
9.3. Age-specific Cases of MPM in the US
9.4. Type-specific Cases of MPM in the US
9.5. Total Incident Cases of MPM by Stages in the US
9.6. Treated cases of MPM in the US

10. EU-5 Epidemiology
10.1. Germany
10.1.1. Total Incident Cases of MPM in Germany
10.1.2. Gender-specific Cases of MPM in Germany
10.1.3. Age-specific Cases of MPM in Germany
10.1.4. Type-specific Cases of MPM in Germany
10.1.5. Total Incident Cases of MPM by Stages in Germany
10.1.6. Treated cases of MPM in Germany
10.2. France
10.2.1. Total Incident Cases of MPM in France
10.2.2. Gender-specific Cases of MPM in France
10.2.3. Age-specific Cases of MPM in France
10.2.4. Type-specific Cases of MPM in France
10.2.5. Total Incident Cases of MPM by Stages in France
10.2.6. Treated cases of MPM in France
10.3. Italy
10.3.1. Total Incident Cases of MPM in Italy
10.3.2. Gender-specific Cases of MPM in Italy
10.3.3. Age-specific Cases of MPM in Italy
10.3.4. Type-specific Cases of MPM in Italy
10.3.5. Total Incident Cases of MPM by Stages in Italy
10.3.6. Treated cases of MPM in Italy
10.4. Spain
10.4.1. Total Incident Cases of MPM in Spain
10.4.2. Gender-specific Cases of MPM in Spain
10.4.3. Age-specific Cases of MPM in Spain
10.4.4. Type-specific Cases of MPM in Spain
10.4.5. Total Incident Cases of MPM by Stages in Spain
10.4.6. Treated cases of MPM in Spain
10.5. The United Kingdom
10.5.1. Total Incident Cases of MPM in the United Kingdom
10.5.2. Gender-specific Cases of MPM in the United Kingdom
10.5.3. Age-specific Cases of MPM in the United Kingdom
10.5.4. Type-specific Cases of MPM in the United Kingdom
10.5.5. Total Incident Cases of MPM by Stages in the United Kingdom
10.5.6. Treated cases of MPM in the United Kingdom

11. Japan Epidemiology
11.1. Total Incident Cases of MPM in Japan
11.2. Gender-specific Cases of MPM in Japan
11.3. Age-specific Cases of MPM in Japan
11.4. Type-specific Cases of MPM in Japan
11.5. Total Incident Cases of MPM by Stages in Japan
11.6. Treated cases of MPM in Japan

12. Current Treatment Practices: Malignant Pleural Mesothelioma (MPM)
12.1. Treatment Algorithm of MPM
12.2. Chemotherapy
12.3. Palliative Procedures
12.4. Surgery
12.5. Radiation Therapy
12.6. Targeted Therapy
12.7. Immunotherapy

13. Guideline of Malignant Pleural Mesothelioma (MPM)
13.1. The American Society of Clinical Oncology (ASCO) Clinical Practice Guideline for MPM
13.2. The National Comprehensive Cancer Network (NCCN) Guidelines for MPM
13.3. The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of MPM

14. Unmet Needs

15. Patient Journey of MPM

16. Key Endpoints in MPM Clinical Trials

17. Marketed Therapies
17.1. NovoTTF-100L System in Combination with Chemotherapy: NovoCure
17.1.1. Product Description
17.1.2. Regulatory Milestones
17.1.3. Other Developmental Activities
17.1.4. Pivotal Clinical Trial
17.2. Opdivo (Nivolumab): Bristol-Myers Squibb/Ono Pharmaceutical
17.2.1. Regulatory Milestone
17.2.2. Other Developmental Activities
17.2.3. Clinical Development
17.2.4. Safety and Efficacy

18. Emerging Therapies
18.1. Key Cross
18.2. TR002: Trizell
18.2.1. Product Description
18.2.2. Clinical Development
18.3. Imfinzi: AstraZeneca
18.3.1. Product Description
18.3.2. Other Developmental Activities
18.3.3. Clinical Development
18.3.4. Safety and Efficacy
18.4. Tecentriq Plus Avastin: Hoffmann-La Roche
18.4.1. Product Description
18.4.2. Other Developmental Activities
18.4.3. Clinical Development
18.5. MesoPher: Amphera BV
18.5.1. Product Description
18.5.2. Other Developmental Activities
18.5.3. Clinical Development

19. Safety and Efficacy
19.1. Pegargiminase: Polaris Pharmaceuticals
19.1.1. Product Description
19.1.2. Other Developmental Activities
19.1.3. Clinical Development
19.1.4. Safety and Efficacy
19.2. Keytruda: Merck Sharp & Dohme Corp.
19.2.1. Product Description
19.2.2. Other Developmental Activities
19.2.3. Clinical Development
19.2.4. Safety and Efficacy
19.3. Galinpepimut-S (Vaccine): Sellas Life Sciences Group
19.3.1. Product Description
19.3.2. Other Developmental Activities
19.3.3. Clinical Development
19.3.4. Safety and Efficacy
19.4. MTG201 Plus Nivolumab: Momotaro-Gene
19.4.1. Product Description
19.4.2. Other Developmental Activities
19.4.3. Clinical Development
19.4.4. Safety and Efficacy
19.5. Lurbinectedin: PharmaMar
19.5.1. Product Description
19.5.2. Other Developmental Activities
19.5.3. Clinical Development
19.5.4. Safety and Efficacy
19.6. Yondelis (trabectedin): PharmaMar
19.6.1. Product Description
19.6.2. Other Developmental Activities
19.6.3. Clinical Development
19.6.4. Safety and Efficacy
19.7. Nintedanib: Boehringer Ingelheim Limited
19.7.1. Product Description
19.7.2. Other Developmental Activities
19.7.3. Clinical Development
19.7.4. Safety and Efficacy
19.8. Avelumab: Pfizer and Merck KGaA
19.8.1. Product Description
19.8.2. Other Developmental Activities
19.8.3. Clinical Development
19.8.4. Safety and Efficacy
19.9. Napabucasin: Sumitomo Dainippon Pharma
19.9.1. Product Description
19.9.2. Other Developmental Activities
19.9.3. Clinical Development
19.10. Anetumab Ravtansine (BAY 94-9343): Bayer/ImmunoGen/MorphoSys
19.10.1. Product Description
19.10.2. Other Developmental Activities
19.10.3. Clinical Development
19.10.4. Safety and Efficacy
19.11. TC-210: TCR2 Therapeutics
19.11.1. Product Description
19.11.2. Other Developmental Activities
19.11.3. Clinical Development
19.12. YS110: Kissei Pharmaceutical
19.12.1. Product Description
19.12.2. Other Developmental Activities
19.12.3. Clinical Development
19.12.4. Safety and Efficacy
19.13. ONCOS-102: Targovax
19.13.1. Product Description
19.13.2. Other Developmental Activities
19.13.3. Clinical Development
19.13.4. Safety and Efficacy
19.14. iCasp9M28z: Atara Biotherapeutics/Bellicum Pharmaceuticals
19.14.1. Product Description
19.14.2. Clinical Development
19.14.3. Safety and Efficacy
19.15. Alisertib (MLN8237): Takeda (Millennium Pharmaceuticals)
19.15.1. Product Description
19.15.2. Other Developmental Activities
19.15.3. Clinical Development

20. Malignant Pleural Mesothelioma (MPM): Seven Major Market Analysis
20.1. Key Findings
20.2. Market Outlook: 7MM

21. 7MM Market Size
21.1. Total Market Size of Malignant Pleural Mesothelioma in the 7MM
21.2. Total Market size of Malignant Pleural Mesothelioma by Therapies in the 7MM

22. United States Market Size
22.1. Total Market size of Malignant Pleural Mesothelioma in the United States

23. EU-5 Market Size
23.1. Germany Market Size
23.1.1. Total Market size of Malignant Pleural Mesothelioma in Germany
23.2. France Market Size
23.2.1. Total Market size of Malignant Pleural Mesothelioma in France
23.3. Italy Market Size
23.3.1. Total Market size of Malignant Pleural Mesothelioma in Italy
23.4. Spain Market Size
23.4.1. Total Market size of Malignant Pleural Mesothelioma in Spain
23.5. United Kingdom Market Size
23.5.1. Total Market size of Malignant Pleural Mesothelioma in the United Kingdom

24. Japan Market Size
24.1. Total Market size of Malignant Pleural Mesothelioma in Japan

25. Market Access and Reimbursement of MPM Therapies
25.1. Issues Associated with Access and Reimbursement of Gene Therapies

26. Market Drivers of MPM

27. Market Barriers of MPM

28. Appendix
28.1. Bibliography
28.2. Report Methodology

29. Publisher Capabilities

30. Disclaimer

31. About the Publisher

List of Tables
Table 1: Summary of MPM Market, Epidemiology, and Key Events (2017–2030)
Table 2: Immunohistochemical Markers for Differentiating Epithelioid Mesothelioma from Other Metastatic Pleural Tumors
Table 3: Immunohistochemical Markers for Differentiating Sarcomatous Mesothelioma from Squamous Cell or Transitional Cell Carcinoma.
Table 4: Stages of MPM
Table 5: Total Incident Cases of Mesothelioma in the 7MM (2017–2030)
Table 6: Total Incident cases of MPM in the 7MM (2017–2030)
Table 7: Gender-specific Cases of MPM in the 7MM (2017–2030)
Table 8: Age-specific Cases of MPM in the 7MM (2017–2030)
Table 9: Type-specific Cases of MPM in the 7MM (2017–2030)
Table 10: Total Incident Cases of MPM by Stages in the 7MM (2017–2030)
Table 11: Treated cases of MPM in the 7MM (2017–2030)
Table 12: Total Incident cases of MPM in the US (2017–2030)
Table 13: Gender-specific Cases of MPM in the US (2017–2030)
Table 14: Age-specific Cases of MPM in the US (2017–2030)
Table 15: Type-specific Cases of MPM in the US (2017–2030)
Table 16: Total Incident Cases of MPM by Stages in the US (2017–2030)
Table 17: Treated cases of MPM in the US (2017–2030)
Table 18: Total Incident cases of MPM in Germany (2017–2030)
Table 19: Gender-specific Cases of MPM in Germany (2017–2030)
Table 20: Age-specific Cases of MPM in Germany (2017–2030)
Table 21: Type-specific Cases of MPM in Germany (2017–2030)
Table 22: Total Incident Cases of MPM by Stages in Germany (2017–2030)
Table 23: Treated cases of MPM in Germany (2017–2030)
Table 24: Total Incident cases of MPM in France (2017–2030)
Table 25: Gender-specific Cases of MPM in France (2017–2030)
Table 26: Age-specific Cases of MPM in France (2017–2030)
Table 27: Type-specific Cases of MPM France (2017–2030)
Table 28: Total Incident Cases of MPM by Stages in France (2017–2030)
Table 29: Treated cases of MPM in Germany (2017–2030)
Table 30: Total Incident cases of MPM in Italy (2017–2030)
Table 31: Gender-specific Cases of MPM in Italy (2017–2030)
Table 32: Age-specific Cases of MPM in Italy (2017–2030)
Table 33: Type-specific Cases of MPM in Italy (2017–2030)
Table 34: Total Incident Cases of MPM by Stages in Italy (2017–2030)
Table 35: Treated cases of MPM in Italy (2017–2030)
Table 36: Total Incident cases of MPM in Spain (2017–2030)
Table 37: Gender-specific Cases of MPM in Spain (2017–2030)
Table 38: Age-specific Cases of MPM in Spain (2017–2030)
Table 39: Type-specific Cases of MPM in Spain (2017–2030)
Table 40: Total Incident Cases of MPM by Stages in Spain (2017–2030)
Table 41: Treated cases of MPM in Spain (2017–2030)
Table 42: Total Incident cases of MPM in the United Kingdom (2017–2030)
Table 43: Gender-specific Cases of MPM in the United Kingdom (2017–2030)
Table 44: Age-specific Cases of MPM in the United Kingdom (2017–2030)
Table 45: Type-specific Cases of MPM in the United Kingdom (2017–2030)
Table 46: Total Incident Cases of MPM by Stages in the United Kingdom (2017–2030)
Table 47: Treated cases of MPM in the UK (2017–2030)
Table 48: Total Incident cases of MPM in Japan (2017–2030)
Table 49: Gender-specific Cases of MPM in Japan (2017–2030)
Table 50: Age-specific Cases of MPM in Japan (2017–2030)
Table 51: Type-specific Cases of MPM in Japan (2017–2030)
Table 52: Total Incident Cases of MPM by Stages in Japan (2017–2030)
Table 53: Treated cases of MPM in Japan (2017–2030)
Table 54: Key Recommendations
Table 55: Levels of evidence and grades of recommendation (adapted from the Infectious Diseases Society of America-United States Public Health Service Grading System
Table 56: Opdivo (Nivolumab), Clinical Trial Description, 2020
Table 57: Key Cross Competition of Emerging Drugs
Table 58: TR002 (Nadofaragene firadenovec; rAd-IFN), Clinical Trial Description, 2020
Table 59: Imfinzi, Clinical Trial Description, 2020
Table 60: Tecentriq Plus Avastin, Clinical Trial Description, 2020
Table 61: MesoPher; Clinical Trial Description, 2020
Table 62: Pegargiminase, Clinical Trial Description, 2020
Table 63: Keytruda, Clinical Trial Description, 2020
Table 64: Galinpepimut-S, Clinical Trial Description, 2020
Table 65: MTG201, Clinical Trial Description, 2020
Table 66: Lurbinectedin, Clinical Trial Description, 2020
Table 67: Trabectedin, Clinical Trial Description, 2020
Table 68: Nintedanib, Clinical Trial Description, 2020
Table 69: Avelumab, Clinical Trial Description, 2020
Table 70: Napabucasin, Clinical Trial Description, 2020
Table 71: Anetumab Ravtansine, Clinical Trial Description, 2020
Table 72: TC-210, Clinical Trial Description, 2020
Table 73: YS110, Clinical Trial Description, 2020
Table 74: ONCOS-102, Clinical Trial Description, 2020
Table 75: iCasp9M28z, Clinical Trial Description, 2020
Table 76: Alisertib (MLN8237), Clinical Trial Description, 2020
Table 77: 7MM Market Size of Malignant Pleural Mesothelioma, in USD Million (2017–2030)
Table 78: 7MM Market Size of Malignant Pleural Mesothelioma by Line of Therapy, in USD Million (2017–2030)
Table 79: 7MM Market Size of Malignant Pleural Mesothelioma by Therapies, in USD Million (2017–2030)
Table 80: United States Market Size of Malignant Pleural Mesothelioma by Line of Therapy, in USD Million (2017–2030)
Table 81: United States Market Size of Malignant Pleural Mesothelioma by Therapies, in USD Million (2017–2030)
Table 82: Germany Market Size of Malignant Pleural Mesothelioma by Line of Therapy, in USD Million (2017–2030)
Table 83: Germany Market Size of Malignant Pleural Mesothelioma by Therapies, in USD Million (2017–2030)
Table 84: France Market Size of Malignant Pleural Mesothelioma by Line of Therapy, in USD Million (2017–2030)
Table 85: France Market Size of Malignant Pleural Mesothelioma by Therapies, in USD Million (2017–2030)
Table 86: Italy Market Size of Malignant Pleural Mesothelioma by Line of Therapy, in USD Million (2017–2030)
Table 87: Italy Market Size of Malignant Pleural Mesothelioma by Therapies, in USD Million (2017–2030)
Table 88: Spain Market Size of Malignant Pleural Mesothelioma by Line of Therapy, in USD Million (2017–2030)
Table 89: Spain Market Size of Malignant Pleural Mesothelioma by Therapies, in USD Million (2017–2030)
Table 90: United Kingdom Market Size of Malignant Pleural Mesothelioma by Line of Therapy, in USD Million (2017–2030)
Table 91: United Kingdom Market Size of Malignant Pleural Mesothelioma by Therapies, in USD Million (2017–2030)
Table 92: Japan Market Size of Malignant Pleural Mesothelioma by Line of Therapy, in USD Million (2017–2030)
Table 93: Japan Market Size of Malignant Pleural Mesothelioma by Therapies, in USD Million (2017–2030)

List of Figures
Figure 1: Malignant Pleural Mesothelioma (MPM) SWOT Analysis
Figure 2: Parts of Lung Affected by Pleural Mesothelioma
Figure 3: Types of MPM
Figure 4: Signs and Symptoms of MPM
Figure 5: Risks Factors of MPM
Figure 6: Pathophysiology of MPM
Figure 7: Hypotheses on Mechanisms that Lead to Neoplastic Transformation of Mesothelial Cells
Figure 8: Algorithm for the Work Up of the Asbestos-exposed Individual who Presents with New Symptoms
Figure 9: Poster Anterior CXR Follow-up Images of Progressive MPM in a 61-year-old Female
Figure 10: Risks Factors of MPM
Figure 11: Global Heat Map of Mesothelioma
Figure 12: Total Incident Cases of Mesothelioma in the 7MM (2017–2030)
Figure 13: Total Incident cases of MPM in the 7MM (2017–2030)
Figure 14: Gender-specific Cases of MPM in the 7MM (2017–2030)
Figure 15: Age-specific Cases of MPM in the 7MM (2017–2030)
Figure 16: Type-specific Cases of MPM in the 7MM (2017–2030)
Figure 17: Total Incident Cases of MPM by Stages in the 7MM (2017–2030)
Figure 18: Treated cases of MPM in the 7MM (2017–2030)
Figure 19: Total Incident cases of MPM in the US (2017–2030)
Figure 20: Gender-specific Cases of MPM in the US (2017–2030)
Figure 21: Age-specific Cases of MPM in the US (2017–2030)
Figure 22: Type-specific Cases of MPM in the US (2017–2030)
Figure 23: Total Incident Cases of MPM by Stages in the US (2017–2030)
Figure 24: Treated cases of MPM in the US (2017–2030)
Figure 25: Total Incident cases of MPM in Germany (2017–2030)
Figure 26: Gender-specific Cases of MPM in Germany (2017–2030)
Figure 27: Age-specific Cases of MPM in Germany (2017–2030)
Figure 28: Type-specific Cases of MPM in Germany (2017–2030)
Figure 29: Total Incident Cases of MPM by Stages in Germany (2017–2030)
Figure 30: Treated cases of MPM in Germany (2017–2030)
Figure 31: Total Incident cases of MPM in France (2017–2030)
Figure 32: Gender-specific Cases of MPM in France (2017–2030)
Figure 33: Age-specific Cases of MPM in France (2017–2030)
Figure 34: Type-specific Cases of MPM France (2017–2030)
Figure 35: Total Incident Cases of MPM by Stages in France (2017–2030)
Figure 36: Treated cases of MPM in France (2017–2030)
Figure 37: Total Incident cases of MPM in Italy (2017–2030)
Figure 38: Gender-specific Cases of MPM in Italy (2017–2030)
Figure 39: Age-specific Cases of MPM in Italy (2017–2030)
Figure 40: Type-specific Cases of MPM in Italy (2017–2030)
Figure 41: Total Incident Cases of MPM by Stages in Italy (2017–2030)
Figure 42: Treated cases of MPM in Italy (2017–2030)
Figure 43: Total Incident cases of MPM in Spain (2017–2030)
Figure 44: Gender-specific Cases of MPM in Spain (2017–2030)
Figure 45: Age-specific Cases of MPM in Spain (2017–2030)
Figure 46: Type-specific Cases of MPM in Spain (2017–2030)
Figure 47: Total Incident Cases of MPM by Stages in Spain (2017–2030)
Figure 48: Treated cases of MPM in Spain (2017–2030)
Figure 49: Total Incident cases of MPM in the United Kingdom (2017–2030)
Figure 50: Gender-specific Cases of MPM in the United Kingdom (2017–2030)
Figure 51: Age-specific Cases of MPM in the United Kingdom (2017–2030)
Figure 52: Type-specific Cases of MPM in the United Kingdom (2017–2030)
Figure 53: Total Incident Cases of MPM by Stages in the United Kingdom (2017–2030)
Figure 54: Treated cases of MPM in the United Kingdom (2017–2030)
Figure 55: Total Incident cases of MPM in Japan (2017–2030)
Figure 56: Gender-specific Cases of MPM in Japan (2017–2030)
Figure 57: Age-specific Cases of MPM in Japan (2017–2030)
Figure 58: Type-specific Cases of MPM in Japan (2017–2030)
Figure 59: Total Incident Cases of MPM by Stages in Japan (2017–2030)
Figure 60: Treated cases of MPM in Japan (2017–2030)
Figure 61: Treatment Algorithm for MPM
Figure 62: Treatment Options of MPM
Figure 63: Unmet Needs
Figure 64: Market Size of Malignant Pleural Mesothelioma in the 7MM, in USD Million (2017–2030)
Figure 65: Market Size of Malignant Pleural Mesothelioma in the 7MM by Line of Therapy, in USD Million (2017–2030)
Figure 66: Market Size of Malignant Pleural Mesothelioma in the 7MM by Therapies, in USD Million (2017–2030)
Figure 67: Market Size of Malignant Pleural Mesothelioma in the United States by Therapy, in USD Millions (2017–2030)
Figure 68: Market Size of Malignant Pleural Mesothelioma in Germany by Therapies, in USD Million (2017–2030)
Figure 69: Market Size of Malignant Pleural Mesothelioma in France by therapies, in USD Million (2017–2030)
Figure 70: Market Size of Malignant Pleural Mesothelioma in Italy by Therapies, in USD Million (2017–2030)
Figure 71: Market Size of Malignant Pleural Mesothelioma in Spain by therapies, in USD Million (2017–2030)
Figure 72: Market Size of Malignant Pleural Mesothelioma in the United Kingdom by Therapies, in USD Million (2017–2030)
Figure 73: Market Size of Malignant Pleural Mesothelioma in Japan by Therapy, in USD Millions (2017–2030)
Figure 74: Market Drivers
Figure 75: Market Barriers
Note: Product cover images may vary from those shown
  • Trizell Ltd
  • AstraZeneca
  • Hoffmann-La Roche
  • Polaris Pharmaceuticals
  • Merck Sharp & Dohme Corp.
  • Sellas Life Sciences Group
  • Momotaro-Gene
  • Bayer/ImmunoGen/MorphoSys
  • PharmaMar
  • MedImmune LLC
  • Boehringer Ingelheim Limited
Note: Product cover images may vary from those shown
Adroll
adroll